Santa Clara, Calif.-based Agilent Technologies has received the CE mark for expanded use of its PD-L1 IHC (immunohistochemistry) 22C3 pharmDx assay for patients with nonsmall-cell lung cancer (NSCLC).

The expanded certification covers use of the assay as an aid in identifying patients with PD-L1 expression in their tumors who can be treated with Regeneron’s antibody Libtayo (cemiplimab).

The assay’s companion diagnostic can help guide treatment decisions for NSCLC, the Santa Clara, Calif.-based company said.